Abstract
Introduction
The anthracycline doxorubicin has the peculiarity of inducing the synthesis of nitric oxide, a small signalling molecule which plays an important role in cell growth, differentiation and apoptosis [1] . 1.14.13.39) gene, leading to the production of huge amounts of nitric oxide [2] . It has been suggested that at least part of the cytotoxic effects elicited by doxorubicin are due to the increased nitric oxide synthesis [3, 4] [5] . By nitrating these proteins on tyrosine residues, nitric oxide reduces Pgp and MRP3 activity, reversing doxorubicin-resistance in solid tumours [4, 6] . Notably, in doxorubicin-resistant cells the induction of iNOS gene is absent, in consequence of the fast drug extrusion; however, when the nitric oxide levels are increased in resistant cells by agents other than doxorubicin, the drug efflux is reduced and the cytotoxicity is restored [4] .
The effect of doxorubicin is mediated by the drug-induced activation of the transcriptional factor NF-B, which in turn up-regulates the transcription of the inducible nitric oxide synthase (iNOS; EC

. Nitric oxide also reduces the rate of doxorubicin efflux through ATP-binding cassette (ABC) membrane pumps, such as P-glycoprotein (Pgp) and multidrug resistance related protein 3 (MRP3), two transporters that are responsible for the resistance towards doxorubicin in cancer cells
A great interest has been raised by the discovery that, besides exerting a direct anticancer effect, anthracyclines also stimulate the host immune response against the tumour [7, 8] . It [8] . Following doxorubicin exposure, a change in tumour cell plasma membrane occurs, leading to the exposure of intracellular proteins, such as calreticulin (CRT) , which is recognized by iDCs and triggers the iDCs-mediated phagocytosis [8, 9] . CRT is usually present in the endoplasmic reticulum (ER) , where it acts as a chaperon and a Ca 2ϩ sensor protein [8, 10] . [6] . These results suggested that chemo-and immunoresistance to doxorubicin are strictly associated, and may both depend on the lack of nitric oxide synthesis in drug-resistant cells.
has been discovered that the anthracyclines immunogenicity relies on their ability to induce the tumour cells phagocytosis by immature dendritic cells (iDCs). After this step, iDCs are stimulated to further maturate and to raise a complete immune response against transformed cells
We have recently demonstrated that doxorubicin mediates the exposure of CRT and the phagocytosis by iDCs thanks to the induction of iNOS in drug-sensitive cells: indeed neither the translocation of CRT nor the phagocytosis occurred in the doxorubicin-sensitive cells silenced for iNOS gene. Doxorubicin was devoid of pro-immunogenic effects also in drug-resistant cells, where the anthracycline was not able to accumulate at a sufficient extent to increase the synthesis of nitric oxide
In [2] (data not shown).
the present work we first investigated the molecular mechanisms by which high levels of nitric oxide induce the translocation of CRT to the cell surface, comparing the doxorubicin-sensitive human colon cancer HT29 cells and the doxorubicin-resistant HT29-dx cells. Moreover we observed that nitric oxide was sufficient to promote the translocation of CRT followed by the phagocytosis in drug-sensitive cells and was necessary to elicit the CRT exposure also in drug-resistant cells, but surprisingly the drug-resistant cells remained poorly phagocitized even in the presence of CRT levels superimposable to sensitive cells. We thus focused on the molecular basis of this strong association between chemo-and immunoresistance, and we analysed whether the increased expression of Pgp in drug-resistant cells may affect the CRT-mediated phagocytosis, thus contributing to their immunoresistant phenotype.
Materials and methods
Materials
Foetal bovine serum (FBS), penicillin-streptomycin (PS) and
Nitrite production
Then nitrite production was measured by adding 0. 15 
Measurement of NOS activity
The procedure described in Ghigo et al. [11] In vitro phagocytosis assay iDCs were generated as described [12] . The 
Intracellular doxorubicin accumulation
Cells were grown in 35-mm-diameter Petri dishes and incubated in RPMI 1640 for 3 hrs with 5 mol/l doxorubicin, and then the intracellular content of the drug was detected fluorimetrically as previously reported [4] . 
Statistical analysis
Results
Doxorubicin fails to increase CRT exposure and HT29 cells phagocytosis when nitric oxide synthesis is inhibited
Doxorubicin increased the activity of NOS enzyme (Fig. 1A) and the synthesis of nitrite (Fig. 1B) Fig. 1A and B) , CRT translocation on plasma membrane (Fig. 1C and D) and phagocytosis (Fig. 1E ) in drug-resistant cells. PTIO and L-NMMA were devoid of effects on all these parameters in HT29-dx cells (Fig. 1A-E) . HT29-dx cells exhibited a basally lower activity of NOS enzyme (Fig. 1A) , a result already reported in this experimental model [6] . Unexpectedly, we observed that the rate of phagocytosis in untreated HT29-dx cells was lower than in HT29 cells (Fig. 1E ). Fig. 2A and B) . On the contrary, ODQ and Rp-8-Br-cGMPS greatly reduced the effect of SNAP ( Fig. 2A and B) . Remarkably, the response to cGMP pathway modulators was similar in doxorubicin-sensitive and doxorubicin-resistant cells.
1C). Doxorubicin also enhanced the phagocytosis of HT29 cells by iDCs, but when the nitric oxide scavenger or the NOS inhibitor were co-incubated with the drug, the phagocytosis was lowered (Fig. 1E). On the contrary, doxorubicin, which was less accumulated in HT29-dx cells [6], did not elicit any increase of nitric oxide synthesis (
Nitric oxide promotes the translocation of CRT in a cGMP-dependent way, via the actin cytoskeleton remodelling
Amongst its several target enzymes, nitric oxide may activate a soluble guanylate cyclase (sGC) and increase the synthesis of cGMP, which in turn promotes the activation of a cGMP-dependent protein kinase (PKG). This event accounts for several effects of nitric oxide such as smooth muscle relaxation, platelet aggregation and cytoskeleton remodelling [13]. Therefore we measured the expression of cell surface CRT in the presence of the nitric oxide donor S-nitrosopenicillamine (SNAP), of the stable cGMP analogue 8-Br-cGMP, of the sGC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ) and of the PKG inhibitor Rp-8-Br-cGMPS. 8-Br-cGMP was as effective as SNAP in inducing the translocation of CRT (
Immunofluorescence analysis revealed that untreated HT29 and HT29-dx cells had no detectable amounts of CRT on plasma membrane, whereas the great majority of the protein was contained within cells (Fig. S1) (Fig. S1 ), as observed in flow cytometry analysis ( Fig. 2A) and biotinylation assay (Fig. 2B) .
A downstream effector of PKG is the VASP, which, after being phosphorylated on serine by PKG, has a prominent role in actin cytoskeleton remodelling [14] : in HT29 and HT29-dx cells the (Fig. 2C) . Total VASP did not vary in any experimental condition (Fig. 2C) .
(E) The phagocytosis of HT29 and HT29-dx cells by iDCs was measured in duplicate by flow cytometry (see 'Materials and methods' for details). Data are presented as means Ϯ S.E. (n ϭ 3). Vs
To (Fig. 3A and B) . Untreated HT29 and HT29-dx cells showed a widespread intracellular actin distribution, with a continuous ring in the sub-plasma membrane region (Fig. 3C) (Fig. 3C) . CRT exposure is increased by nitric oxide in both HT29 and HT29-dx cells, but is followed by phagocytosis only in doxorubicin-sensitive cells TNF-␣, a potent inducer of iNOS, significantly increased the NOS activity (Fig. 4A) , the nitrite levels (Fig. 4B ) and the CRT translocation ( Fig. 4C and D) in both doxorubicin-sensitive and doxorubicinresistant cells. PTIO, which lowered the levels of nitrite (Fig. 4B) without affecting per se NOS activity (Fig. 4A) , also decreased the exposure of CRT (Fig. 4C and D) . In parallel TNF-␣ induced, whereas PTIO reduced, the index of phagocytosis of HT29 cells by iDCs (Fig. 4E) . Despite the increase of nitrite and CRT, TNF-␣ did not induce the iDCs-mediated uptake of HT29-dx cells, which were less phagocytized than drug-sensitive cells in each experimental condition (Fig. 4E) .
Doxorubicin and the nitric oxide donor SNAP per se increased the nitrite levels (Fig. 5A ) and the CRT exposure (Fig. 5C and D ) in HT29 cells, displaying an additive effect when co-incubated (Fig. 5A, C and D) . SNAP did not modify the activity of NOS, which was raised by doxorubicin in sensitive cells and remained superimposable to the control cells in all the other conditions (Fig. 5B) , but increased the nitrite amounts by releasing nitric oxide (Fig. 5A) . When SNAP was co-incubated with doxorubicin in doxorubicin-resistant cells, where the drug alone was devoid of effect, the nitrite amount was significantly increased (Fig. 5A ) and the CRT exposure was induced (Fig. 5C and D) . Cisplatin, an anticancer agent which did not affect the nitric oxide synthesis (Fig. 5A and B) was not able to elicit any translocation of CRT (Fig. 5C and D) or to promote the phagocytosis (Fig. 5E) . However, when SNAP was added to cisplatin, the CRT expression became detectable in plasma membrane (Fig. 5C and D) and the uptake of HT29 cells by iDCs was significantly raised (Fig. 5E) Fig. 5C and  D) , but the phagocytosis did not (Fig. 5E ). [4, 6] (Fig. 6) . In HT29 cells, where the expression of Pgp was low (Fig. 7A) , we did not detect any association between Pgp and CRT (Fig. 6A) (Fig. 7B) . (Fig. 7C) , were poorly phagocytized, similar to HT29-dx cells (Fig. 7D) . However, in the presence of doxorubicin or SNAP, which both increased the surface CRT levels in HT29-dx Pgp -cells (Fig. 7C) , (Fig. 7D ). [15, 16] . Anthracyclines, like doxorubicin, are useful tools in the chemoimmunotherapy, because they are the only anticancer drugs with a proved stimulating effect on macrophages [17] , lymphocytes [18] and DCs [8] . [19] and as an inhibitor of the doxorubicin efflux through ABC transporters [4, 6] . We [6] .
dissociation between the CRT exposure and the phagocytosis was observed in HT29-dx cells, where in the presence of cisplatin plus SNAP, the CRT translocation on cell surface increased (
These data gave us further evidence that nitric oxide, generated by an iNOS inducer as well as released by a nitric oxide donor, was necessary to promote the CRT translocation in both doxorubicin-sensitive and doxorubicin-resistant tumour cells, but it was sufficient to induce phagocytosis by iDCs only in the drug-sensitive ones.
In HT29-dx cells CRT is associated to Pgp, which exerts an inhibitory effect on the phagocytosis
To analyse why the increased amount of surface CRT was not relatable to an increased phagocytosis in HT29-dx cells, we investigated whether Pgp, a membrane protein which is overexpressed in HT29-dx cells, but not in HT29 cells
, might interfere with the functional activity of the surface CRT or with the phagocytosis of drugresistant cells. We first assessed if Pgp was physically associated to CRT: we immunoprecipitated with an anti-CRT antibody the cell extracts enriched with the ER membranes (where the vast majority of CRT resides) or containing the cell surface biotinylated proteins; then we probed the immunoprecipitated samples with an anti-Pgp antibody
. On the contrary, in ER extracts derived from HT29-dx cells, Pgp co-immunoprecipitated with CRT (Fig. 6A). Such an association was detected in untreated cells and was not affected by doxorubicin or SNAP (Fig. 6A). The nitric oxide donor SNAP was the only agent able to induce the exposure of CRT in the plasma membrane in HT29-dx cells (Figs 5B, C and 6B): following SNAP incubation, we observed a co-immunoprecipitation of CRT and Pgp also in the cell extracts containing surface biotinylated proteins (Fig. 6B). This phenomenon was absent in untreated cells and in HT29-dx cells exposed to doxorubicin (Fig. 6B). Such a result suggests that Pgp was bound to CRT in ER and that this association was not lost during the translocation on the plasma membrane of doxorubicin-resistant cells. To further clarify whether the interaction between CRT and Pgp has a functional role in the immunoresistance of HT29-dx cells, we knocked down Pgp with a siRNA approach. Besides reducing the protein expression levels in HT29-dx cells (Fig. 7A), the silencing of Pgp raised the accumulation of doxorubicin to a level superimposable to that of not-silenced HT29-dx cells treated with SNAP
Fig. 4 Effects of TNF-␣ on doxorubicin-induced
the silencing of Pgp induced the uptake by iDCs, suggesting that the overexpression of Pgp exerts a negative control on the CRT-dependent phagocytosis of drug-resistant cells
Discussion
The combination of conventional anticancer drugs to immunostimulating agents has recently obtained promising results in tumour mice models and in clinical trials
Most anticancer drugs elicit in tumour cells an apoptotic death, which is considered not immunogenic, in opposition to a necrotic death, which releases in the microenvironment several tumour antigens, recognized by iDCs [8]. Doxorubicin exerts both an apoptotic and an immunogenic cell death: indeed following the drug administration, several intracellular proteins, like CRT, are exposed on the plasma membrane and trigger the tumour cells uptake by iDCs [8]. Besides inducing CRT translocation, doxorubicin is also able to increase the synthesis of nitric oxide, which may act as a tumoricidal agent, as an immunomodulator agent
In the present work we first investigated by which mechanisms nitric oxide could exert such an effect. In chemosensitive HT29 
cells incubated with doxorubicin, in the presence of a nitric oxide scavenger or a NOS inhibitor, the nitrite increase elicited by the anthracycline, the CRT translocation and the cells phagocytosis by iDCs were all reduced. On the contrary, in drug-resistant HT29-dx cells, where nitric oxide levels were not modulated by doxorubicin, PTIO and NMMA, CRT translocation and phagocytosis by iDCs remained low. Interestingly, NOS activity was lower in untreated HT29-dx cells than in HT29 cells, although no significant difference was detected in the nitrite levels between these cell populations:
such a discrepancy is likely due to the higher sensitivity of the spectrophotometric assay of NOS activity towards the colorimetric Griess method for nitrite detection [11] . We did not observe any variation in the total CRT expression, despite significant changes in the CRT levels on the plasma membrane. Most CRT usually resides in ER and is absent on plasma membrane, where only small amounts of CRT translocate; it has been suggested that, although the fraction of CRT in ER does not change, small variations in the plasma membrane fraction may be sensed as an effective 'eat me' signal by iDCs [9] . The appearance of small but detectable amounts of CRT was a powerful eating marker also in our experimental model. This event has been reported to be the first step a more complex activation of the host immune system against the tumour.
For example the exposure of CRT on the mouse CT26 colon cells surface has been shown to trigger the activation of immune system cells in mice xenografts [9] and the up-regulation of CRT gene in colon cancers with microsatellite instability has been associated with a more pronounced lymphocytic infiltrate, a more active immune response and a better prognosis of patients [20] . In keeping with these observations, we have previously observed that in HT29 cells the CRT exposure increased the tumour cell uptake and the progression of immature DCs to an antigen-presenting mature phenotype [6] .
Several mechanisms have been invoked to explain how CRT appears on the plasma membrane following anthracyclines administration. Because such translocation occurs in both enucleated and nucleated tumour cells, the increase of CRT on the cell surface is not attributable to augmented gene transcription [9] . Some 
subjected to ultracentrifugation to isolate the ER-enriched fraction (A). In parallel, in an aliquot of cells incubated under the same experimental conditions, the surface proteins were isolated by a biotinylation assay (B). Each sample was immunoprecipitated (IP) with an anti-CRT antibody and probed with an anti-Pgp or an anti-CRT antibody by
